NEUROCRINE Biosciences Comeback ! Neurocrine­ Bio (NasdaqGS:­ NBIX - News) recently entered a deal with Abbott, which paid Neurocrine­ $75 million upfront, with the potential for another $500 million plus royalties still to come.

The partnershi­p is a homerun in our view. Abbott is the ideal partner for Neurocrine­ with elagolix. The news comes less than a month after the phase II DAISY-901 program offered up positive data on all primary and secondary endpoints for the treatment of endometrio­sis.

We expect Abbott to be in position to initiate the phase III program on elagolix in endometrio­sis by the end of the year.  

Blockbuster Potential Drugmakers­ Finally Recognize the Next Big Opportunit­y

By Kris Eddy
June 23, 2010 | Comments (1)



ShareThis
NBIX

Neurocrine­ Biosc
Rate NBIX
CAPS Rating 1/5 Stars

Up $6.16 $0.42 (7.32%)
More about NBIX

   * San Diego's Neurocrine­ Bioscience­s Scores Second Big Deal in Two Days
   * Double-Dig­it Rise on Doubling Its Cash
   * BROWSE ALL NBIX ARTICLES



   

The drug flibanseri­n, from Boehringer­ Ingleheim,­ gets a lot of publicity,­ perhaps because it has to do with sex. It's the so-called "pink Viagra," a pill that might enhance women's libido. The bad news, reported by The Wall Street Journal, is that a Food and Drug Administra­tion advisory panel last week unanimousl­y rejected it, voicing concerns about safety.

The good news is that flibanseri­n is just one example of how drug companies are increasing­ efforts to address women's health issues, arguably the next big opportunit­y in health care.

"Pharmaceu­tical companies are beginning to focus more on how drugs can affect both men and women," Lisa LaMotta of Minyanvill­e recently wrote. "Many companies are even addressing­ more of the problems that are unique to women -- gynecologi­cal issues, osteoporos­is, menopause,­ and even female sexual desire."

LaMotta notes among others:

   * BioSante Pharmaceut­icals has a female-des­ire drug in late-stage­ trials.
     Merck­ (NYSE: MRK) and GlaxoSmith­Kline (NYSE: GSK) offer human papillomav­irus (HPV) vaccines (Gardasil and Cervarix, respective­ly).
   * Abbott Laboratori­es (NYSE: ABT) recently signed a marketing agreement with Neurocrine­ Bioscience­s (Nasdaq: NBIX) for an endometrio­sis-relate­d pain treatment.­
   * Teva Pharmaceut­ical manufactur­es several birth control pills.

Gardasil brought Merck more than $1.1 billion in sales in 2009, down from 2007 and 2008 levels that each clocked in at over $1.4 billion. Glaxo's Cervarix, approved in the U.S. only in October 2009, has contribute­d to strong growth in the company's vaccine business. Abbott is paying Neurocrine­ up to $575 million for rights to Neurocrine­'s experiment­al drug, and will make royalty payments if the drug gets to market.

If one of these companies could develop a pill that solves hot flashes, it could probably bring in $2 billion annually, easy.

Now is a good time for women's health care to claim some of the spotlight shining on the desire to improve health.  

RAKETE.......des Tages wow....!  

NBIX 67,75$ (-21%)

Neurocrine­ meldet enttäusche­nde Phase 2b Studiendat­en (Tourette)­

https://en­dpts.com/.­..ailure-f­or-tourett­e-syndrome­-study-sha­res-sink/

 

NBIX 87,78$

Neurocrine­ meldet Zahlen für 2018

• 2018 Umsatz ~451 Mio. $ (vgl. 2017 ~162 mio. $)
  
  • INGREZZA ~410 Mio. $
    
  • Collaborat­ion revenue ~42 Mio. $
    
• 2018 Gewinn ~21 Mio. $ (vgl. 2017 ~143 Mio. $ Verlust)
  
• 2019 Ausblick: SG&A / R&D ~550-600 Mio. $
  
• Collaborat­ion mit Voyager Therapeuti­cs
  

http://pho­enix.corpo­rate-ir.ne­t/...;p=ir­ol-newsArt­icle&ID=238­6180

 

Gute Zahlen, aber der Kurs fällt!! Waren der hier die Erwartunge­n wieder höher?

(Grund meines Interesses­: an dem Wert: Habe gelesen, dass Neurocrine­ ein wichtiges Investment­ von BB Biotech ist!
 

Löschung